1. Home
  2. EMO vs MNKD Comparison

EMO vs MNKD Comparison

Compare EMO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearBridge Energy Midstream Opportunity Fund Inc.

EMO

ClearBridge Energy Midstream Opportunity Fund Inc.

HOLD

Current Price

$50.56

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$3.93

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMO
MNKD
Founded
2011
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
EMO
MNKD
Price
$50.56
$3.93
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $8.08
AVG Volume (30 Days)
31.6K
★ 3.4M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 6.70%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $348,966,000.00
Revenue This Year
N/A
$26.63
Revenue Next Year
N/A
$14.81
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 22.23
52 Week Low
$41.54
$2.23
52 Week High
$56.33
$6.51

Technical Indicators

Market Signals
Indicator
EMO
MNKD
Relative Strength Index (RSI) 51.28 63.51
Support Level $49.73 $3.24
Resistance Level $53.33 $4.28
Average True Range (ATR) 1.09 0.15
MACD 0.29 0.08
Stochastic Oscillator 49.81 96.08

Price Performance

Historical Comparison
EMO
MNKD

About EMO ClearBridge Energy Midstream Opportunity Fund Inc.

ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: